CG Oncology/$CGON
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Ticker
- $CGON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Dallas, United States
- Website
- cgoncology.com
CG Oncology Metrics
BasicAdvanced
$5.7B
-
-$2.72
0.24
-
Price and volume
Market cap
$5.7B
Beta
0.24
52-week high
$80.97
52-week low
$35.80
Average daily volume
1M
Financial strength
Current ratio
22.219
Quick ratio
21.776
Long term debt to equity
0.008
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-249.663
Gross margin (TTM)
-2,593.69%
Net profit margin (TTM)
-3,602.68%
Operating margin (TTM)
-4,056.18%
Management effectiveness
Return on assets (TTM)
-17.67%
Return on equity (TTM)
-26.41%
Valuation
Price to revenue (TTM)
855.601
Price to book
5.55
Price to tangible book (TTM)
5.61
Price to free cash flow (TTM)
-29.712
Free cash flow yield (TTM)
-3.37%
Free cash flow per share (TTM)
-2.177
Growth
Revenue change (TTM)
1,030.31%
Earnings per share change (TTM)
53.47%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
Analyst projections of the future price of CG Oncology stock.
Bulls say / Bears say
The published Phase 3 BOND-003 results showed a 75.5% complete response rate and 60.1% response durability at 24 months, with no Grade 3 or higher treatment-related adverse events. This supports cretostimogene’s potential as a durable bladder-sparing treatment. (The Lancet Oncology)
Early Phase 2 CORE-008 results for cretostimogene plus gemcitabine showed an 85.7% complete response rate in the intention-to-treat CIS group and 89.5% high-grade event-free survival at six months overall. These findings could broaden the drug’s potential, although follow-up remains short. (CG Oncology)
CG Oncology had about $1.0 billion in cash and marketable securities at the end of June, which it expects to fund operations through 2029. It also expects to complete its first BLA submission in the fourth quarter of 2026, giving it financial room to prepare for a potential launch. (CG Oncology)
BOND-003 was a single-arm Phase 3 study, without a randomised control group. Its results therefore do not directly show how cretostimogene compares with other treatments, which leaves uncertainty around its relative clinical benefit. (The Lancet Oncology)
Cretostimogene’s potential in intermediate-risk disease still depends on PIVOT-006, a Phase 3 trial whose topline results the company listed as an upcoming milestone in its latest quarterly update. Until those results are known, the case for expanding into that patient group remains unproven. (CG Oncology)
The company has no approved product and reported a $79.1 million net loss for the second quarter, with research and administrative expenses both rising year on year. It must secure approval and build sales before it can offset those continuing costs. (CG Oncology)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
CG Oncology News
AllArticlesVideos
Funds containing CG Oncology
Fund name | Fund size | $CGON weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.43% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.43% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.43% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.36% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.